Avanos reports Q3 adjusted EPS 22c, consensus 12c

Reports Q3 revenue $177.8M, consensus $164.5M. “I am pleased with our third quarter results, both operationally and commercially,” said David Pacitti, Avanos (AVNS)’ CEO. Pacitti continued, “Avanos delivered double-digit growth in our life-sustaining Specialty Nutrition Systems segment and made continued progress in our opioid-sparing Pain Management and Recovery segment, all while managing through a challenging tariff environment. In addition, we are excited about the recently completed acquisition of Nexus Medical, which adds complementary technology to our Specialty Nutrition Systems offerings and is expected to deliver immediate value in NICU and PICU care.”